Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Rhea-AI Summary

Lyell Immunopharma (NASDAQ: LYEL), a clinical-stage biotech company focused on developing next-generation CAR T-cell therapies for cancer patients, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's senior management team will deliver a presentation on Wednesday, June 11th, 2025, at 10:00 am ET. Investors and interested parties can access the live webcast through the Investors section of Lyell's website at www.lyell.com. A replay of the presentation will be made available on the company's website after the event.

News Market Reaction

-14.92%

1 alert

-14.92% News Effect

On the day this news was published, LYEL declined 14.92%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11^th at 10:00 am ET.

A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date.

About Lyell Immunopharma, Inc.

Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit www.lyell.com.

Contact:

Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com

FAQ

When is Lyell Immunopharma (LYEL) presenting at the Goldman Sachs Healthcare Conference 2025?

Lyell Immunopharma will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11th, 2025, at 10:00 am ET.

How can investors access Lyell Immunopharma's (LYEL) Goldman Sachs conference presentation?

Investors can access the live webcast through the Investors section of Lyell's website at www.lyell.com, and a replay will be available after the presentation.

What type of therapies is Lyell Immunopharma (LYEL) developing?

Lyell Immunopharma is developing next-generation CAR T-cell therapies for patients with cancer.

Is Lyell Immunopharma (LYEL) a commercial or clinical-stage company?

Lyell Immunopharma is a clinical-stage company developing cancer therapies.